Update on neuromyelitis optica spectrum disorder.

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Current Opinion in Ophthalmology

• Publication date

  2020-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/ICU.0000000000000703PMID 33009077PMCID PMC7771018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder

  2020cited by this paper
• Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.

  2020cited by this paper
• Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

  2020cited by this paper
• Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders.

  2020cited by this paper
• Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD).

  2020cited by this paper
• Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy.

  2020cited by this paper
• Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography

  2020cited by this paper
• Striking neurologic 18F-FDG PET/CT pattern in Devic’s disease (neuromyelitis optica spectrum disorder)

  2019cited by this paper
• Treating neuromyelitis optica with azathioprine: 20-year clinical practice

  2019cited by this paper
• Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment.

  2019cited by this paper
• Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

  2019cited by this paper
• Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.

  2019cited by this paper
• Brain and cord imaging features in neuromyelitis optica spectrum disorders

  2019cited by this paper
• Immunoadsorption or plasma exchange in steroid‐refractory multiple sclerosis and neuromyelitis optica

  2019cited by this paper
• Rituximab during pregnancy in neuromyelitis optica: A case report

  2019cited by this paper
• Neuromyelitis optica spectrum disorders.

  2019cited by this paper
• Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.

  2019cited by this paper
• Autonomic dysfunction in people with neuromyelitis optica spectrum disorders

  2019cited by this paper
• Neuromyelitis Optica with Lesions Involving the Optic Nerves, the Optic Chiasm, and the Optic Tracts

  2019cited by this paper
• Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders

  2019cited by this paper
• Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease.

  2019cited by this paper
• Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset

  2019cited by this paper
• Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries.

  2019cited by this paper
• A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder

  2019cited by this paper
• Late Onset of Neuromyelitis Optica Spectrum Disorders

  2019cited by this paper
• In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis

  2019cited by this paper
• Late-onset neuromyelitis optica spectrum disorder

  2019cited by this paper
• Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

  2019cited by this paper
• Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica

  2019cited by this paper
• Sexual dysfunction in patients with neuromyelitis optica spectrum disorder.

  2019cited by this paper
• Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee

  2019cited by this paper
• A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX.

  2019cited by this paper
• Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea

  2019cited by this paper
• Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

  2019cited by this paper
• Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody.

  2019cited by this paper
• Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis

  2019cited by this paper
• Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders

  2018cited by this paper
• Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders

  2018cited by this paper
• Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease.

  2018cited by this paper
• Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate.

  2018cited by this paper
• Mortality in neuromyelitis optica is strongly associated with African ancestry

  2018cited by this paper
• Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment

  2018cited by this paper
• Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica.

  2018cited by this paper
• A prospective case-control study comparing optical coherence tomography characteristics in neuromyelitis optica spectrum disorder- optic neuritis and idiopathic optic neuritis

  2018cited by this paper
• A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica

  2018cited by this paper
• Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review.

  2018cited by this paper
• Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women

  2018cited by this paper
• Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders.

  2018cited by this paper
• Open-label, add-on trial of cetirizine for neuromyelitis optica

  2018cited by this paper
• Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders

  2018cited by this paper
• Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders

  2018cited by this paper
• Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

  2018cited by this paper
• Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

  2018cited by this paper
• Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders

  2018cited by this paper
• Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity

  2017cited by this paper
• Incidence and prevalence of NMOSD in Australia and New Zealand

  2017cited by this paper
• Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan

  2017cited by this paper
• Neuromyelitis optica spectrum disorders in Iran.

  2017cited by this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

  2016cited by this paper
• Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)‐6 produced during remission phase

  2016cited by this paper
• Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum

  2016cited by this paper
• Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange

  2016cited by this paper
• International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

  2015cited by this paper
• Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis

  2013cited by this paper
• Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System

  2012cited by this paper
• Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

  2011cited by this paper
• A secondary progressive clinical course is uncommon in neuromyelitis optica

  2007cited by this paper
• Revised diagnostic criteria for neuromyelitis optica

  2006cited by this paper
• Effects of speech rate on the absolute and relative timing of apraxic and conduction aphasic sentence production.

  1990cited by this paper

• Neurological and paraclinical features differentiating Systemic lupus erythematosus, Sjögren's disease, and neuromyelitis optica spectrum disorders.

  2026cites this paper
• Brain health - time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report.

  2025cites this paper
• Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review.

  2025cites this paper
• Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis

  2025cites this paper
• SPHERES: innovative registry addressing the new era of neuromyelitis optica spectrum disorders (NMOSD) therapy.

  2025cites this paper
• Insights into neuromyelitis optica spectrum disorder and pregnancy from a single-center study in Thailand

  2025cites this paper
• Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance

  2025cites this paper
• Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and mixed connective tissue disease: a case report

  2025cites this paper
• A roadmap to increasing access to AQP4-Ig testing for NMOSD: expert recommendations

  2024cites this paper
• Disease characteristics of NMOSD and their relationship with disease burden: Observations from a large single-center cohort.

  2024cites this paper
• A Chinese child with both systemic lupus erythematosus coexisting with neuromyelitis optica spectrum disorder: a case report

  2024cites this paper
• Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.

  2024cites this paper
• Single-cell RNA sequencing reveals cell type-specific immune regulation associated with human neuromyelitis optica spectrum disorder

  2024cites this paper
• Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor

  2024cites this paper
• Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance

  2024cites this paper
• Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.

  2023cites this paper
• Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis

  2023cites this paper
• Aquaporin‐4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants

  2023cites this paper
• Central Nervous System Neuroimmunologic Complications of COVID-19

  2023cites this paper
• White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease

  2023cites this paper
• Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data

  2023cites this paper
• Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis

  2023cites this paper
• Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.

  2023cites this paper
• The association between body mass index, demographic and clinical characteristics with cognitive performance in patients with neuromyelitis optica spectrum disorder

  2022cites this paper
• Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

  2022cites this paper
• The role of autophagy-related proteins in the pathogenesis of neuromyelitis optica spectrum disorders

  2022cites this paper
• Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder.

  2022cites this paper
• Research progress of single-cell transcriptome sequencing in autoimmune diseases and autoinflammatory disease: A review.

  2022cites this paper
• Autoimmune Neurologic Emergencies.

  2021cites this paper
• Optic Neuritis Presented as Syndrome of Inappropriate Antidiuretic Hormone Secretion in an 8 Year Old

  2021cites this paper
• Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice

  2021cites this paper
• Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents

  2021cites this paper
• Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort.

  2021cites this paper
• Neuromyelitis Optica Spectrum Disorder Manifested by Persistent Hiccups and Severe Esophagitis in an Adolescent Patient

  2021cites this paper